 |
Jaehyung Yoon
|
10/07/09 9:46 AM |
CTIC
|
Analysis |
thestreet.com/st...o.html
thestreet.com/st...z.html I am not a big fan of Adam
Feuerstein, because he is often negative about his commentaries,
but ...
|
173
|
-
|
 |
Jaehyung Yoon
|
10/07/09 9:00 AM |
CTIC
|
News |
CTIC is one of the most controversial
biotech receiving a lot of heat from many analysts including Adam
Feuerstein. The stock has dropped from $1.74 to...
|
135
|
-
|
 |
Jaehyung Yoon
|
09/15/09 10:57 PM |
PDLI
|
Analysis |
Existing licensed marketed products:
Genentech, Inc.: Herceptin® (trastuzumab),
Xolair® (omalizumab), Raptiva® (efalizumab), ...
|
112
|
-
|
 |
Jaehyung Yoon
|
09/02/09 8:42 AM |
GENZ
|
News |
Genzyme Corporation Announces FDA Advisory
Committee Recommends Randomized Trial To Support Proposed
Indication For Clolar In Adult AML Tuesday, 1 Sep 2009 0...
|
62
|
-
|
 |
Jaehyung Yoon
|
08/26/09 11:05 PM |
ONTY
|
Analysis |
Assigning a value to development-stage
biotech companies is a questionable task, and generally requires
more intangible assumptions (market potential, clinic...
|
1832
|
1
|
 |
Jaehyung Yoon
|
08/14/09 11:18 AM |
ARIA
|
-
|
Justin Hall on Seeking Alpha posted a very
in-dept analysis of the company, technology, and the opportunity,
so here is the link: seekingalpha.com/in...achi...
|
246
|
-
|
 |
Jaehyung Yoon
|
08/13/09 10:20 PM |
ARIA
|
Analysis |
I think given the volatility and the
spotlight that biotech has received, this is a good company to
place a small amount of our hard-earned money for a specu...
|
2447
|
3
|
 |
Jaehyung Yoon
|
08/10/09 2:00 PM |
GENZ
|
News |
I don't know enough to compare/contrast
Genzyme and Shire in depth, but here are the major differences on
the surface: Genzyme is a biotechnology company, a...
|
50
|
1
|
 |
Jaehyung Yoon
|
08/07/09 9:01 AM |
OREX
|
News |
July 20, 2009: Orexigen Therapeutics, Inc.
Announces Contrave Obesity Research Phase 3 Program Meets
Co-Primary And Key Secondary Endpoints; Exceeds FDA Effi...
|
46
|
-
|
 |
Jaehyung Yoon
|
08/07/09 8:45 AM |
GENZ
|
News |
Genzyme's blockbuster product in the
genetic disorder is Cerezyme for Gaucher diseases. Comparable
to the blockbuster are Shire's velaglucerase alfa an...
|
54
|
2
|